Single dose of New Limit's cellular reprogramming therapy improves survival in alcohol liver damage mouse models over multiple months of repeated alcohol cycles
New Limit has developed a single-dose cellular reprogramming therapy that significantly improves survival rates in mice with alcohol-induced liver damage. This therapy restores the liver's youthful resilience and regenerative capacity, rather than just speeding up alcohol metabolism. The treatment utilizes mRNA encoding transcription factors, delivered via lipid nanoparticles, a technology similar to that used in COVID-19 vaccines. Human trials are planned for next year in Australia. AI
IMPACT This research demonstrates a novel application of mRNA and LNP technology for regenerative medicine, potentially influencing future therapeutic development.